Migraine remains a common debilitating condition that exerts a high social and economic burden worldwide. Despite the widespread availability of various medications for migraine, many patients are dissatisfied with their treatment. Rapid and effective treatment at an early stage in an attack is vital in migraine to prevent central sensitization leading to attacks that are difficult to treat. Most migraineurs prefer oral medications but this is not always the most rapid or efficient route into the bloodstream. Intranasal administration of migraine treatment provides a rapid, convenient and reliable alternative to oral and other routes. AVP-825 is an intranasal medication delivery system approved by the US Food and Drug Administration in January 2016 as ONZETRA™ Xsail™ (sumatriptan nasal powder [Avanir Pharmaceuticals, Aliso Viejo, CA]) for the acute treatment of migraine with or without aura in adults. AVP-825 contains low dose sumatriptan powder and takes advantage of some unique aspects of the nasal anatomy to confer rapid pain relief in the acute treatment of migraine. In two Phase III trials, AVP-825 was well tolerated and showed significantly faster migraine pain relief and relief from other symptoms including photophobia, phonophobia, and nausea than placebo or oral sumatriptan. This benefit was achieved with substantially lower drug exposure than oral sumatriptan. Additional analyses of data from the Phase III trials show that significantly more patients with migraine receiving AVP-825 reported clinically meaningful relief, sustained relief, pain freedom, lower migraine-related disability and more consistent relief across multiple attacks than those receiving oral sumatriptan. The rapid and sustained action of AVP-825 and its convenience creates the potential for this unique treatment to reduce the burden of migraine in many patients.
nasal valve, into the upper posterior nasal cavity, an area conducive to the rapid systemic absorption of medication, while reducing off-target delivery to the front of the nose or the diversion of the drug to the throat and gastrointestinal (GI) tract. The evidence supporting AVP-825 and its potential importance as a new approach to managing migraine is reviewed herein.

**The need for rapid pain relief in acute migraine**

Both episodic and chronic migraine are generally under-diagnosed and under-treated; patient management is frequently suboptimal and relies primarily on over-the-counter medications or oral triptans. In the acute treatment of migraine, patients want medications that provide rapid relief, freedom from pain within 2 hours, relief from other symptoms such as photophobia, phonophobia, and nausea, no recurrence or longer times to recurrence, no need for rescue medication, efficacy that is maintained and does not decrease on subsequent attacks, absence of side effects, and oral administration. In order to achieve these goals, ideal patient management should therefore include disease education, avoidance of potential trigger factors and an individually tailored, evidence-based treatment plan that is reassessed at frequent intervals.

In the acute treatment of migraine, rapid delivery of medication at the optimal dose may improve effectiveness and treatment satisfaction by preventing progression of the migraine cycle. Effective treatment should be available for use early in an attack with back-up medications in case of treatment failure, as the response to any treatment cannot be predicted with certainty. Multiple formulations of medication delivery should be part of a treatment plan which stratifies use based on the characteristics of the patient’s migraine attack, while considering the presence of significant nausea or vomiting, the patient’s ability to tolerate odors and flavors during a migraine, speed of headache onset, presence of migraine upon awakening, and severity of pain.

Fast acting treatments provide the best opportunity to treat during the early stages of an attack when it may be terminated fully. If left untreated, second- and third-order trigeminal neurons may become activated leading to central sensitization and allodynia. Once this occurs, the attack is much harder to treat, and triptans may be less effective. Nonetheless, fewer than half of patients using triptans to treat their migraines use them early. When comparing patients who employed triptans early from those who delayed treatment, the reasons for delaying treatment were: taking over-the-counter medications or a non-triptan first, waiting to be certain that a headache was a migraine, and only taking a triptan if the over-the-counter or non-triptan medication did not work. Other factors contributing to treatment delay included concern of running out of triptans, dislike of taking medications, concern about side effects, and cost. By reducing the duration of pain and the other associated symptoms of migraine (e.g., photophobia, phonophobia, nausea, and vomiting), rapid acting therapies may enable an earlier resumption of work/leisure activities and are likely to improve quality of life.

**Triptans and other acute treatments for migraine**

The majority of prescriptions for migraine-specific medications are oral triptans. Sumatriptan was the first to emerge and has the most options in terms of formulation. Second generation triptans include naratriptan, zolmitriptan, eleetroptan, almotriptan, rizatriptan, and frovatriptan. Although most patients prefer oral administration of migraine therapy, it is often associated with delayed and unreliable onset of relief due to slow or inconsistent gastric emptying and delayed absorption particularly during a migraine episode. In addition, patients often delay taking oral medications due to migraine-related nausea.

There are multiple alternative triptan formulations designed to bypass the GI tract with efficacy generally superior to oral administration, but their utilization in current clinical practice has been limited. Local tolerability issues specific to the site of administration, along with the occurrence of triptan-related adverse effects such as tingling, and chest, jaw, or neck tightness (i.e., atypical sensations) may impact tolerability, preference, and adherence despite the potential efficacy advantages of non-oral triptan formulations.

The triptans were first introduced as treatments for migraine over 25 years ago but non-steroidal anti-inflammatory drugs (NSAIDs) remain widely used. This is largely due to their availability without a prescription, familiarity, effectiveness in mild attacks, and mostly favorable side effect profiles. These treatments include acetylsalicylic acid, ibuprofen, diclofenac, metamizole, naproxen sodium, indomethacin, and ketoprofen. NSAIDs are mainly given orally but some can be administered rectally or parenterally in cases that are resistant to treatment or in emergencies. In addition, NSAIDs and/or acetaminophen/paracetamol can be effective and are frequently used in combination with caffeine. NSAIDs appear to be effective for mild to moderate migraine attacks, however, they are associated with a risk for GI adverse effects, including bleeding. High dose levels may be required for NSAIDs to be effective and they are also used in combination with an anti-emetic to reduce migraine-associated nausea and vomiting. Ergotamines have been used for up to 50 years in migraine treatment and may be useful in patients with intermittent or long-lasting attacks. Other treatments include analgesics such as opiates, which are not advised for routine use and are mainly reserved as rescue medication.

In a survey of 688 migraineurs conducted in the US, among 23% who expressed some dissatisfaction with their medication, 87% said pain relief took too long, 84% said treatment effect was inconsistent, and 71% said that the pain recurred. In addition, 71% said that pain relief should occur within <30 minutes. In total, 90% of patients prefer the convenience of oral administration over alternative routes. However, the slower onset of effect of oral medications compared with subcutaneous injection or intranasal delivery, along with the challenges associated with the administration of non-oral formulations may contribute to patient dissatisfaction.

**Current sumatriptan delivery systems**

Sumatriptan is available as oral tablets, subcutaneous injections, liquid intranasal sprays, rectal suppositories (Europe only), and an iontophoretic transdermal patch (the sale and marketing of the iontophoretic transdermal system was suspended on June 10, 2016 pending investigation by the FDA of reports of burning and scarring related to use of the device). A Cochrane review of clinical trials showed that among study participants with migraine, the numbers needed to treat (NNT) to reduce pain from moderate or severe to none or mild by two hours were: subcutaneous injection: 2.3 (6 mg, n=2,738), oral: 3.5 (100 mg, n=7,811), intranasal liquid: 3.5 (20 mg, n=2,020), and rectal: 2.4 (25 mg, n=240). The transdermal patch, which was not included in the Cochrane review, showed an NNT of 4.1 (n=454) based on data from a Phase III pivotal trial. In this review subcutaneous administration was apparently the most effective and fastest route, but it is less...
convenient than oral or nasal administration and is associated with more adverse events and higher costs. Whilst these NNTs provided interesting comparisons between administration routes, their clinical meaningfulness remains unclear.

The benefits of non-oral migraine therapies
Delivery of triptans via non-oral routes avoids issues involving GI absorption and hepatic first-pass metabolism, both of which can delay the onset of effect and diminish the efficacy of orally administered medications in migraine. These attributes are particularly important for patients with a rapid onset of migraine pain, migraine present upon awakening, or significant nausea or vomiting during attacks. Injection or intranasal delivery may improve bioavailability, reduce loss of drug due to metabolism, and decrease the risk of GI adverse events. While bioavailability of the subcutaneous injection is high, the bioavailability of treatments delivered intranasally by traditional liquid spray is reduced because a portion of the medication settles on the floor of the anterior nasal cavity and travels to the back of the throat, where it is swallowed. Medication that is diverted to the GI tract is subject to the same shortcomings of traditional oral delivery such as slower absorption and lower systemic bioavailability.

Nasal anatomy and migraine treatment administration
When considering nasal delivery devices and mechanisms, it is important to keep in mind that the main purpose of the nasal airway is to protect the lungs from hazardous exposures. To take full advantage of the nasal passage as a delivery route for drugs, several features of nasal anatomy, physiology, and aerodynamics must be taken into account to ensure rapid and efficient drug delivery. The nasal valve and the complex tortuous nasal geometry are among the most important hurdles for efficient nasal drug delivery into the systemic circulation. The anterior portion of the nasal cavity is a small region lined with squamous epithelium designed to protect the body from inhaled particles and toxic substances, properties which are not ideal for efficient drug delivery. The posterior nasal cavity, located beyond the narrow nasal valve, has a large surface area lined with columnar respiratory epithelium that is richly supplied from a vascular bed of highly permeable capillaries, allowing for rapid absorption of drug directly into the circulation. In order to achieve optimal uptake and optimal pharmacodynamics, medications must efficiently and reliably be deposited in the posterior nasal cavity beyond the nasal valve.

Because the posterior nasal cavity is difficult to reach, it is under-used as a site of drug administration. Liquid nasal sprays often fail to fully penetrate beyond the nasal valve, as inhalation tends to create negative pressure within the nasal cavity and narrow the nasal valve passage. Because the anterior nasal cavity is small and lined with squamous epithelium, liquid medication deposited in the anterior portion of the nose tends to settle on the nasal cavity floor and a substantial portion travels to the back of the throat, often resulting in complaints of an unpleasant or bitter taste which may further perpetuate nausea or vomiting during a migraine attack. An ideal intranasal product, particularly for the migraineur, would minimize drug deposition in the anterior nasal cavity and maximize the amount delivered beyond the nasal valve in order to reach the large absorptive mucosal surfaces of the posterior nasal cavity.

AVP-825—a breath-powered delivery system for sumatriptan nasal powder
AVP-825 is an intranasal medication delivery system containing 11 mg sumatriptan powder per nosepiece, with two nosepieces comprising...
Table 1: Overview of key clinical trials in the development of the AVP-825* in the treatment of migraine

<table>
<thead>
<tr>
<th>Study and reference</th>
<th>Study design and patient numbers</th>
<th>Treatments</th>
<th>Endpoints</th>
<th>Key findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase I PK Obaidi et al., 2013a</td>
<td>Randomized, open-label, four-way crossover, single-dose study in healthy adult subjects (n=20)</td>
<td>AVP-825 versus oral, liquid nasal spray and subcutaneous injection sumatriptan formulations</td>
<td>PK parameters (C_{\text{max}}, t_{\text{max}}, AUC)</td>
<td>AVP-825 showed higher and earlier (C_{\text{max}}) and (AUC_{0-24}) minutes versus liquid nasal spray. Faster absorption and greater systemic exposure over the first 15-minute post-dose versus oral sumatriptan. Lower peak and overall systemic exposure versus oral or subcutaneous injection of sumatriptan.</td>
</tr>
<tr>
<td>Phase II Djupesland et al., 2013a</td>
<td>Randomized, double-blind, pbo-controlled, parallel group, single-attack study in adults with moderate or severe episodic migraine ± aura (n=117)</td>
<td>AVP-825 delivering sumatriptan powder 10 mg** or 20 mg** versus pbo in same delivery system</td>
<td>Efficacy, (pain freedom and pain relief up to 120 minutes and 48 hours post dosing), tolerability and safety</td>
<td>AVP-825 10 mg** or 20 mg** treatment resulted in significantly greater freedom from pain after 2-hour post-dose versus pbo (p=0.05). Significantly more subjects in both dose groups were pain-free at 120 minute versus pbo (p=0.01).</td>
</tr>
<tr>
<td>Phase III TARGET Cady et al., 2015a, McAllister et al., 2015a</td>
<td>Randomized, double-blind, pbo-controlled, parallel group, single-attack study in adults with episodic, moderate or severe migraines ± aura (n=230)</td>
<td>AVP-825 versus pbo in same delivery system</td>
<td>Efficacy, (reduction of headache pain intensity from severe or moderate migraine headache to mild or none after hours), tolerability and safety</td>
<td>Significantly more patients who received AVP-825 treatment reported headache relief at 2 hours after treatment compared with pbo delivered using the same system (p=0.002). This was maintained up to 48 hours. Significantly more patients receiving AVP-825 treatment were pain free at 2 hours compared with pbo (p=0.008). Treatment with AVP-825 produced a significant reduction in migraine-associated clinical disability and improved function in patients receiving AVP-825 treatment versus pbo (p=0.05). The treatment was well tolerated with few systemic AEs.</td>
</tr>
<tr>
<td>Phase III COMPASS Tepper et al., 2015a</td>
<td>Randomized, double-blind, active-comparator, crossover, multi-attack study in adults with mild, moderate or severe, episodic migraine ± aura (n=275)</td>
<td>AVP-825 + pbo tablet versus pbo delivery system + 100 mg oral sumatriptan tablet</td>
<td>Efficacy, (mean summed pain intensity differences through 30 minutes post-dose (\text{SPID-30}), tolerability and safety</td>
<td>AVP-825 treatment resulted in significantly greater reduction in migraine pain through 30-minutes post-dose (\text{SPID-30}) versus high-dose oral sumatriptan (p&lt;0.001). The proportions of attacks with pain relief and pain freedom from 15 minutes to 90 minutes were significantly greater with the AVP-825 than with oral sumatriptan, were similar at 2 hours and remained so until end of follow-up at 48 hours after dosing. Few adverse events occurred with AVP-825 which were mainly nasal disturbance and abnormal taste. Incidence of treatment emergent atypical sensations were significantly lower with AVP-825 treatment versus oral sumatriptan.</td>
</tr>
</tbody>
</table>

*The amount of drug delivered from the AVP-825 device during in vitro testing was 10 mg. **AVP-825 was approved by the FDA on January 28, 2016 as ONZETRA™ Xsail™ (sumatriptan nasal powder) 11 mg. The dose reported in the Phase 2 study is the amount of drug delivered from one nosepiece during in vitro testing (i.e., 10 mg) is equivalent to the labelled dose based on the amount of dry powder sumatriptan base filled into a capsule (i.e. 11 mg). AE = adverse events; AUC 0-30 = area under the curve during first 30 minutes post dose; C_{\text{max}} = maximal plasma concentration; COMPASS = AVP-825* breath powered intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines; pbo = placebo; PK = pharmacokinetic; TARGET = A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825 exhaler) in the Treatment of Acute Migraine

---

a single 22 mg dose (~15–16 mg sumatriptan delivered intranasally) (Figure 2).\(^{18,19,20}\) When inserted properly into one nostril, the sealing cone-shaped nosepiece of the exhaler makes a tight seal and expands the narrow opening of the nasal valve. After pressing a button to pierce the sumatriptan containing capsule, the patient blows into the opening of mouthpiece for 2-3 seconds to create a positive pressure differential in the oral cavity. This raises the oropharyngeal velum (soft palate), which separates the oral and nasal cavities, helping to prevent lung deposition and limiting diversion of drug into the GI tract. After passing through the nosepiece of the device, the exhaled breath carries the sumatriptan powder deep into the nasal cavity where it is deposited on the mucosal surface of the posterior nasal cavity. Breathing into the device balances pressure across the soft palate to assure an open connection between the two sides of the nasal cavity, as the breath continues around the septum and out of the other nostril (Figure 3). Sumatriptan powder delivered this way is more efficient and produces earlier exposure and faster absorption with a lower dose than either liquid nasal spray or oral administration.\(^{20}\)

**Clinical trials supporting the use of AVP-825 in migraine**

AVP-825 has been studied in a series of randomized Phase I, II, and III studies (total n=642), which were either placebo-controlled or comparative in design (Table 1). In these clinical trials, all subjects were trained on the use of the device prior to treatment, and study results demonstrate that users of AVP-825 can complete proper dose administration with and without formal training. All subjects in clinical trials were able to demonstrate the ability to use the breath powered device correctly and, presence of moderate nasal congestion (e.g. due to common cold or allergic rhinitis) was not a reason for exclusion in the clinical trials. Those with an uncontrolled nasopharyngeal illness or known nasal obstruction due to nasal septum deviation, polyps or severe mucosal swelling were excluded.
In an early randomized open label, cross-over, pharmacokinetic (PK) Phase I study (n=20), healthy subjects received four sequential single doses of sumatriptan with 7-day wash-out intervals between treatments consisting of AVP-825 (containing 22 mg intranasal sumatriptan powder), 20 mg sumatriptan liquid nasal spray, 100-mg sumatriptan oral tablet, and 6 mg sumatriptan subcutaneous injection.\textsuperscript{50} The results showed that AVP-825 was a more efficient method of sumatriptan delivery, producing a higher peak plasma concentration (C\textsubscript{max}) and a faster rise in plasma concentration (t\textsubscript{max}) with a lower delivered dose (16 mg) than nasal spray and faster absorption than either nasal spray or oral administration. AVP-825 increases sumatriptan bioavailability by 27\% compared to oral tablets, and by 36\% compared to liquid nasal spray administration.

The absorption of sumatriptan into the bloodstream (10-15 minute area under the curve) and the plasma drug concentration profiles indicated that AVP-825 produced greater sumatriptan blood concentrations than nasal spray or oral tablets over the first 15 minutes after dosing (Figure 4),\textsuperscript{50} despite a lower delivered dose, and a significantly lower peak and total systemic exposure than oral tablet or subcutaneous injection.

In a randomized, double-blind, placebo-controlled, Phase II study, participants with episodic migraine (n=117) were treated with AVP-825 (either 11 mg or 22 mg sumatriptan) or placebo during a single migraine attack of moderate to severe intensity.\textsuperscript{51} The results showed that AVP-825 provided a significantly greater rate of pain freedom (54\% and 57\% for 11 mg or 22 mg, respectively versus 25\% for placebo, p<0.05 for both comparisons) and pain relief (84\% and 80\% for 11 mg or 22 mg respectively versus 44\% for placebo, p<0.001 and p<0.01, respectively) at 2 hours after dosing compared with placebo.\textsuperscript{52} In this study, AVP-825 doses were well tolerated and treatment-related adverse events were generally mild and transient.

The Phase III TARGET study (for definition of study names see Table 1)\textsuperscript{53} was a randomized, double-blind, placebo-controlled, parallel group single attack study (n=230) in which participants with migraine headaches of moderate or severe intensity were treated using AVP-825 (22 mg) or a matching placebo delivery system containing lactose powder.\textsuperscript{51} Significantly more patients receiving AVP-825 versus placebo reached the primary outcome of headache relief, defined as a change in pain severity from severe or moderate to mild or none at 120 minutes post-dose (68\% versus 45\%, p=0.002), with statistical significance demonstrated at every time point from 30 minutes (42\% versus 27\%, p=0.03) through 2 hours (Figure 5). AVP-825 was well tolerated and associated with few systemic adverse events. Local adverse events that were reported more frequently following treatment with AVP-825 versus placebo, respectively, were local site reactions including abnormal taste (22\% versus 4\%), nasal discomfort (13\% versus 2\%), rhinorrhea (5\% versus 3\%), and rhinitis (3\% versus 0\%), with the majority of each of these events described as mild. In addition, nearly 90\% of subjects in the TARGET study reported that the delivery system was easy to use.

The Phase III COMPASS study was a randomized, double-blind, multi-attack, double-dummy, head-to-head, crossover study (n=275)
Statistical comparisons in favor of oral sumatriptan. At no time point and for no efficacy endpoint were the greater consistency across multiple migraines with AVP-825 versus oral in this study treated multiple attacks and demonstrated significantly using AVP-825 versus oral sumatriptan. The majority of participants associated symptoms (photophobia, phonophobia and nausea), as well attacks treated with AVP-825 produced early reductions in migraine-

Table 2: Overview of post-hoc analyses of the Phase II, COMPASS and TARGET clinical trials of AVP-825 in the treatment of migraine

<table>
<thead>
<tr>
<th>Study reference</th>
<th>Parameters analyzed</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cady et al., 201554</td>
<td>Exploratory analysis of response in pts by baseline headache intensity</td>
<td>AVP-825 treatment improved headache severity in pts with moderate or severe migraine versus placebo. Pts with moderate or severe baseline headache had high early response to AVP-825 treatment and substantial benefit at 24 and 48 hours despite low systemic exposure. There was a greater difference between drug and placebo effect when baseline headache intensity was severe.</td>
</tr>
<tr>
<td>McAllister et al., 201554</td>
<td>Migraine disability and functional outcome</td>
<td>AVP-825 treatment produced early and efficient migraine benefit, with a high percentage of early responders and sustained relief up to 48 hours. With headache relief there were significant early improvements in function versus placebo at 45 minutes; 42% of AVP-825 -treated pts had no disability, 81% had mild or no disability at 120 minutes. AVP-825 produced minimal triptan-related effects.</td>
</tr>
<tr>
<td>Winner et al., 201554</td>
<td>Efficacy analysis by prior triptan history</td>
<td>In pts previously treated with multiple triptans, AVP-825 treatment produced rapid relief and superior efficacy versus placebo on multiple measures of headache. The difference in AVP-825 treatment between ≥2 triptan subgroup versus ≤1 triptan subgroup was not statistically significant for pain relief, suggesting that response to treatment with AVP-825 was consistent and not influenced by number of prior triptans used. The absolute difference in response rates for AVP-825 versus placebo was greater for pts who had previously used multiple triptans than for pts with one or no prior triptan exposure.</td>
</tr>
</tbody>
</table>

**COMPASS study**

| Lipton et al., 201557 | Consistency of response | AVP-825 treatment produced more consistent pain freedom and pain relief in multiple migraine attacks at 30 minutes post treatment versus 100 mg oral sumatriptan. This is consistent with the PK advantage of breath powered intranasal delivery of sumatriptan powder. |

**Combined analysis of Phase II, TARGET & COMPASS studies**

| Cady et al., 201555 | Pooled analyses of randomized, double-blind, placebo-controlled studies | Pooled results from placebo-controlled Phase II and III studies confirm the findings of the individual trials regarding the efficacy and safety of AVP-825 which confers rapid headache relief that is sustained through 48 hours. The treatment was well tolerated; adverse events were mainly administration-site and were mild and transient. AVP-825 will constitute an important treatment option for patients with migraine. |

COMPASS = AVP-825 breath powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines; PK = pharmacokinetic; pts = patients; TARGET = A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825 exhaler) in the Treatment of Acute Migraine.

(Figure 6).53 Patients with 2–8 migraines/month were randomized (1:1) to either AVP-825 (22 mg) + oral placebo tablet or an identical placebo delivery system containing lactose powder + 100 mg oral sumatriptan tablet for up to a 12-week duration after which treatments were crossed-over for a second 12-week treatment period. Patients were instructed to treat ≥5 attacks within one hour of onset in each treatment period. A total of 185 (67.3%) participants treated at least one migraine in both periods and were analyzed for efficacy; a total of 1,531 migraines were assessed (765 AVP-825, 766 oral sumatriptan). Participants receiving treatment with AVP-825 + placebo tablet experienced significantly greater reduction in migraine summed pain intensity difference in the first 30 minutes after dosing (SPID-30) compared with participants receiving high-dose oral sumatriptan tablet + placebo device (p<0.001).53 Significantly greater rates of both pain freedom and pain relief were observed with AVP-825 versus oral sumatriptan as early as 15 minutes and at every time point through 90 minutes post-dose. After 2 hours, the rates of pain relief and pain freedom were similar for both treatments and remained so for up to 48 hours (Figure 7A and 7B). Significantly more attacks treated with AVP-825 produced early reductions in migraine-associated symptoms (photophobia, phonophobia and nausea), as well as early improvement in clinical disability and meaningful relief after using AVP-825 versus oral sumatriptan. The majority of participants in this study treated multiple attacks and demonstrated significantly greater consistency across multiple migraines with AVP-825 versus oral sumatriptan. At no time point and for no efficacy endpoint were the statistical comparisons in favor of oral sumatriptan.

![Figure 6: Design and patient disposition in the COMPASS trial of AVP-825 treatment versus oral sumatriptan in the treatment of migraine attacks](http://example.com/figure6.png)

Treatment with AVP-825 was well tolerated with no serious adverse events and a safety profile similar to that reported in other controlled trials. The most frequent adverse events for AVP-825 and sumatriptan (100 mg) were abnormal taste (26% versus 4% respectively) and nasal discomfort (16% versus 1%, respectively), of which approximately 90% were mild. In addition, there was a lower incidence of triptan-related atypical
sensations after dosing with AVP-825 versus 100 mg oral sumatriptan (2% versus 5%; p=0.02). The greater efficacy over the first 90 minutes and the similar efficacy over 2–48 hours were achieved despite the fact that AVP-825 delivers a substantially smaller systemic exposure to the drug than the 100 mg sumatriptan tablet.

**Evidence supporting AVP-825 in migraine from additional analyses of the TARGET and COMPASS study data**

Additional/post-hoc analyses of prospectively collected outcomes from the TARGET and COMPASS studies based on patient subgroups and several secondary endpoints have produced further insights into the value of AVP-825 in the treatment of migraine. These are summarized in Table 2.

In the TARGET study, a secondary outcome analysis showed that pain-freedom at 2 hours was achieved by significantly more participants using AVP-825 than with placebo (34% versus 17%, p=0.008); in addition, significantly more enrollees treated with AVP-825 reported sustained pain relief, defined as pain relief within 120 minutes and no use of rescue medication or relapse within 24 and 48 hours post-dose, compared with placebo.

Additional analysis of the TARGET study data showed that significantly more participants receiving treatment with AVP-825 versus placebo reported meaningful relief at 120 minutes post-dose (70% versus 45%, p<0.001), and no disability at 120 minutes post dose (42% versus 27%) (Table 2). In addition, treatment with the AVP-825 effectively reduced headache severity in participants with either moderate or severe migraine compared with placebo, with greater improvement observed in participants who treated headaches of more severe intensity at baseline.

A further TARGET study analysis explored the efficacy of AVP-825 relative to placebo based on history of previous treatment with triptans prior to enrollment in the study. Statistically significant separation from placebo was achieved as early as 30 minutes (47.1% versus 23.1%, p<0.05) and at all time points through 120 minutes (61.8% versus 35.0%, p<0.05) in patients who had previously used at least two triptans. Significant separation was also seen from 60 minutes (57.5% versus 40.6%, p<0.05) through 120 minutes (70.3% versus 51.6%, p<0.05) for those who had previously used one or no triptans. The probability of being a responder to placebo tended to be greater in the ≤1 triptan subgroup than in the ≥2 triptan subgroup, which drove the differences in statistical separation at earlier time points. Analysis of the difference in response to AVP-825 treatment based on number of prior triptans used was not statistically significant for pain relief, suggesting that response to treatment with AVP-825 was consistent and not influenced by number of prior triptans used.

In the COMPASS study, most subjects treated 2–5 migraines in a treatment period (95% AVP-825, 92% oral sumatriptan), and treatment outcomes with AVP-825 were more consistent across multiple migraine attacks compared with 100 mg oral sumatriptan in participants who treated ≥2 attacks (n=165), and in participants who treated ≥3 attacks in each period (n=140).

A pooled analysis of the data from all of the placebo-controlled Phase II and III studies (Table 2) of AVP-825 examined outcomes of pain relief, pain freedom, clinical disability, migraine-associated symptoms, meaningful relief, use rescue medication and safety profile. The analysis confirmed the individual study findings demonstrating that AVP-825 is generally well tolerated and confers rapid early efficacy that is sustained through 48 hours.

**Discussion and conclusion**

Migraine is a highly debilitating disease that continues to exert heavy social and economic burdens. Triptan therapies have improved treatment effectiveness and extended therapeutic choices but more rapid relief of migraine pain remains a significant unmet medical need. This is emphasized by the finding that most patients would be willing to try another medication for acute treatment of their headaches. A potential
weakness of oral delivery of migraine medications is the delayed or inconsistent onset of relief due to slow or erratic GI absorption especially when most needed – during a migraine attack. Migraine-related nausea predicts a poor response to oral triptans and can also cause patients to delay treatment options, further compromising therapeutic efficacy.20

AVP-825 is a novel treatment that takes advantage of nasal anatomy and physiology to provide an efficient method of drug delivery. AVP-825 uses the patient’s own breath to propel low dose sumatriptan powder into the upper posterior nasal cavity, an area potentially conducive to the rapid absorption of medication into the systemic circulation. The unique shape of the nosepiece in conjunction with the air pressure from exhalation helps to widen the nasal valve allowing for targeted delivery to the posterior nasal cavity, and closure of the soft palate may help prevent lung deposition and limits diversion of drug into the GI tract.

The primary findings of prospective, randomized, placebo-controlled studies, demonstrated that AVP-825 provided early onset of efficacy for migraine without loss of sustained efficacy over multiple attacks, and was associated with a low risk of systemic triptan-related adverse events. The meaningfulness of the treatment effect was emphasized by the post-hoc analyses and secondary endpoints. In a blinded comparative study across multiple attacks, AVP-825 provided an earlier reduction of migraine pain intensity and higher rates of pain relief and pain freedom from 15 through 90 minutes, without loss of sustained efficacy despite a lower peak and systemic exposure than the most effective dose of oral sumatriptan (100 mg). AVP-825 was well tolerated, with an overall tolerability profile similar among the Phase II and III studies. Most treatment emergent adverse events were associated with local administration site effects such as nasal discomfort and abnormal product taste, with the majority of cases reported as mild.

Future research on AVP-825 is needed to confirm long-term efficacy and determine how other patient outcomes, including migraine-related disability and migraine-associated symptoms such as nausea, change over time as a function of treatment. AVP-825 is indicated only for the acute treatment of migraine with or without aura in adults, and further studies would be needed to determine if intranasal treatment might benefit patients with cluster headache and migraine disorders other than episodic migraine, as well as other populations (e.g., adolescents). The extensive available trial data and additional analyses show that AVP-825 has the potential to improve the treatment of acute migraine, having rapid onset of therapeutic effect across multiple attacks, less systemic drug exposure, and low rates of triptan-related adverse events.  

21. Brandes L, Buchanan TM, Welch KMA, Symptomatic treatment of migraine: when most needed – during a migraine attack. Migraine-related nausea predicts a poor response to oral triptans and can also cause patients to delay treatment options, further compromising therapeutic efficacy. AVP-825 is a novel treatment that takes advantage of nasal anatomy and physiology to provide an efficient method of drug delivery. AVP-825 uses the patient’s own breath to propel low dose sumatriptan powder into the upper posterior nasal cavity, an area potentially conducive to the rapid absorption of medication into the systemic circulation. The unique shape of the nosepiece in conjunction with the air pressure from exhalation helps to widen the nasal valve allowing for targeted delivery to the posterior nasal cavity, and closure of the soft palate may help prevent lung deposition and limits diversion of drug into the GI tract.

The primary findings of prospective, randomized, placebo-controlled studies, demonstrated that AVP-825 provided early onset of efficacy for migraine without loss of sustained efficacy over multiple attacks, and was associated with a low risk of systemic triptan-related adverse events. The meaningfulness of the treatment effect was emphasized by the post-hoc analyses and secondary endpoints. In a blinded comparative study across multiple attacks, AVP-825 provided an earlier reduction of migraine pain intensity and higher rates of pain relief and pain freedom from 15 through 90 minutes, without loss of sustained efficacy despite a lower peak and systemic exposure than the most effective dose of oral sumatriptan (100 mg). AVP-825 was well tolerated, with an overall tolerability profile similar among the Phase II and III studies. Most treatment emergent adverse events were associated with local administration site effects such as nasal discomfort and abnormal product taste, with the majority of cases reported as mild.

Future research on AVP-825 is needed to confirm long-term efficacy and determine how other patient outcomes, including migraine-related disability and migraine-associated symptoms such as nausea, change over time as a function of treatment. AVP-825 is indicated only for the acute treatment of migraine with or without aura in adults, and further studies would be needed to determine if intranasal treatment might benefit patients with cluster headache and migraine disorders other than episodic migraine, as well as other populations (e.g., adolescents). The extensive available trial data and additional analyses show that AVP-825 has the potential to improve the treatment of acute migraine, having rapid onset of therapeutic effect across multiple attacks, less systemic drug exposure, and low rates of triptan-related adverse events.

Review  Migraine


57. Lipton RB, Buse DC, Shulman K, et al., Consistency of response in the COMPASS Study (Breath Powered™ nasal delivery of 22 mg sumatriptan powder (AVP-825) versus 100 mg oral sumatriptan in acute migraine: a comparative clinical trial, Presented at 38th Annual Meeting of the Society of General Internal Medicine, Toronto, Canada, April 2015.